Alzheimer's Foundation of America
Select text size: a | a | a
 

Clinical Trials

Find a Trial

To find a trial, please view the list below. Also visit www.clinicaltrials.gov.

Search by State:
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
PENNSYLVANIA

Location: Abington
Abington Memorial Hospital

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Sondra B. Mabry
215-481-2402

Back to Top

Location: Allentown
Lehigh Valley Hospital

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Deborah R. Kane
610-402-0581
deborah.kane@lvh.com

Back to Top

Location: Bethlehem
St. Luke's Hospital and Health Network

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Kelly A. Filchner
610-954-3582

Back to Top

Location: Doylestown
Doylestown Hospital

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Karen E. Quinlan
215-345-2866

Back to Top

Location: Jenkintown
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild to Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Not yet recruiting

Study Dates: Start: January 2007

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Marvin Kalafer
877-379-3718

Back to Top

Location: Philadelphia
University of Pennsylvania

Trial Title and Description: Anti-Oxidant Treatment of Alzheimer's Disease-

The purpose of this study is to examine the safety and effectiveness of two anti-oxidant treatment regimens in patients with mild to moderate Alzheimer's disease. The anti-oxidant treatments include vitamin E + C + alpha-lipoic acid, and Coenzyme Q (CoQ).

Enrollment Status: Recruiting

Study Dates: Start: January 2006

Condition: Alzheimer's disease
Age Eligibility: 60-85
Gender Eligibility: Both
Enrollment Goal: 75
Clinical Identifier: NCT00117403
Study Phase: Phase 1
Study Type: Interventional

Sponsor: National Institute on Aging (NIA)

Contact Information:
Monica Hann
215-349-5903
monica.han@uphs.upenn.edu

Gerri Anselmo
215-662-4377
gerri.anselmo@uphs.upenn.edu

Christopher Clark

Back to Top

Location: Philadelphia
University of Pennsylvania

Trial Title and Description: Depression in Alzheimer's Disease-

The purpose of this study is to learn whether treating individuals with Alzheimer's disease and depression with the anti-depressant medication Sertraline (Zoloft) is helpful to people with Alzheimer's disease and to their families and caregivers.

Enrollment Status: Recruiting

Study Dates: Start: July 2004

Condition: Alzheimer's disease, Depression
Age Eligibility: 18 and above
Gender Eligibility: Both
Enrollment Goal: 130
Clinical Identifier: NCT00086138
Study Phase: Phase 2,3
Study Type: Interventional

Sponsor: National Institute of Mental Health (NIMH)

Contact Information:
Suzanne DiFilippo
215-349-8228
difilipp@mail.med.upenn.edu

Trisha Stump
215-349-8227
tstump@mail.med.upenn.edu

Back to Top

Location: Philadelphia
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild to Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Not yet recruiting

Study Dates: Start: January 2007

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Joel Streim
877-379-3718

Carol Lippa
877-379-3718

Back to Top

Location: York
York Cancer Center / Wellspan Health

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Cecil Runyons
859-257-1412 ext. 235
preadvise@lsu.uky.edu

Back to Top

RHODE ISLAND

Location: Providence
Rhode Island Hospital

Trial Title and Description: A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease

The purpose of this study is to determine whether IGIV, 10% treatment, administered at two different doses for 9 and 18 months, results in a significantly slower rate of decline of dementia symptoms in subjects with mild to moderate Alzheimer’s Disease (AD). Subjects will be randomly assigned to receive intravenous infusions of either of two doses of IGIV, 10% or placebo every two weeks for 70 weeks (36 infusions) as an add-on to conventional Food and Drug Administration (FDA)-approved AD medications.

Enrollment Status: Recruiting
Study Dates: Start: December 2008
Condition: Alzheimer’s disease
Age Eligibility: 50-89
Gender Eligibility: Both
Enrollment Goal: 360
Clinical Identifier: NCT00818662
Study Phase: Phase 3
Study Type: Interventional

Sponsor: Baxter Healthcare Corporation

Contact Information:
Michele Astphan
401-444-2484
mastphan@lifespan.org
For more information, visit www.gapstudy.com

Back to Top

Location: Providence
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy to Acetylcholinesterase Inhibitors In Mild To Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD) when combined with one of the currently approved AD medications, Aricept®, Razadyne® or Exelon®. RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Recruiting

Study Dates: Start: July 2006

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Stephen Salloway
877-379-3718

Back to Top

SOUTH CAROLINA

Location: N. Charleston
Medical University of South Carolina

Trial Title and Description: A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease

The purpose of this study is to determine whether IGIV, 10% treatment, administered at two different doses for 9 and 18 months, results in a significantly slower rate of decline of dementia symptoms in subjects with mild to moderate Alzheimer’s Disease (AD). Subjects will be randomly assigned to receive intravenous infusions of either of two doses of IGIV, 10% or placebo every two weeks for 70 weeks (36 infusions) as an add-on to conventional Food and Drug Administration (FDA)-approved AD medications.

Enrollment Status: Recruiting
Study Dates: Start: December 2008
Condition: Alzheimer’s disease
Age Eligibility: 50-89
Gender Eligibility: Both
Enrollment Goal: 360
Clinical Identifier: NCT00818662
Study Phase: Phase 3
Study Type: Interventional

Sponsor: Baxter Healthcare Corporation

Contact Information:
Arthur Williams
843-740-1592, ext 17
alwpoe@musc.edu
For more information, visit www.gapstudy.com

Back to Top

Location: North Charleston
Medical University of South Carolina

Trial Title and Description: Anti-Oxidant Treatment of Alzheimer's Disease-

The purpose of this study is to examine the safety and effectiveness of two anti-oxidant treatment regimens in patients with mild to moderate Alzheimer's disease. The anti-oxidant treatments include vitamin E + C + alpha-lipoic acid, and Coenzyme Q (CoQ).

Enrollment Status: Recruiting

Study Dates: Start: January 2006

Condition: Alzheimer's disease
Age Eligibility: 60-85
Gender Eligibility: Both
Enrollment Goal: 75
Clinical Identifier: NCT00117403
Study Phase: Phase 1
Study Type: Interventional

Sponsor: National Institute on Aging (NIA)

Contact Information:
Stephanie Kirbach
843-740-1592
kirbach@musc.edu

Andrew Larkin
larkina@musc.edu

Aljoeson Walker

Back to Top

Location: North Charleston
Medical University of South Carolina

Trial Title and Description: Depression in Alzheimer's Disease-

The purpose of this study is to learn whether treating individuals with Alzheimer's disease and depression with the anti-depressant medication Sertraline (Zoloft) is helpful to people with Alzheimer's disease and to their families and caregivers.

Enrollment Status: Recruiting

Study Dates: Start: July 2004

Condition: Alzheimer's disease, Depression
Age Eligibility: 18 and above
Gender Eligibility: Both
Enrollment Goal: 130
Clinical Identifier: NCT00086138
Study Phase: Phase 2, 3
Study Type: Interventional

Sponsor: National Institute of Mental Health (NIMH)

Contact Information:
Martie Hatchell
843-740-1592, ext. 20
hatchell@musc.edu

Marilyn Stuckey
843-740-1592, ext. 13
stuckeym@musc.edu

Back to Top

Location: North Charleston
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild to Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Not yet recruiting

Study Dates: Start: January 2007

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Jacob Mintzer
877-379-3718

Back to Top

SOUTH DAKOTA

Location: Sioux Falls
Sioux Community Cancer Consortium

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Judy Norman
605-331-3257
cincod@cpc-clinics.com

Back to Top

TENNESSEE

Location: Cordova
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild to Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Not yet recruiting

Study Dates: Start: January 2007

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Lee Stein
877-379-3718

Back to Top

Location: Franklin
Psychiatric Consultants

Trial Title and Description: A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease

The purpose of this study is to determine whether IGIV, 10% treatment, administered at two different doses for 9 and 18 months, results in a significantly slower rate of decline of dementia symptoms in subjects with mild to moderate Alzheimer’s Disease (AD). Subjects will be randomly assigned to receive intravenous infusions of either of two doses of IGIV, 10% or placebo every two weeks for 70 weeks (36 infusions) as an add-on to conventional Food and Drug Administration (FDA)-approved AD medications.

Enrollment Status: Recruiting
Study Dates: Start: December 2008
Condition: Alzheimer’s disease
Age Eligibility: 50-89
Gender Eligibility: Both
Enrollment Goal: 360
Clinical Identifier: NCT00818662
Study Phase: Phase 3
Study Type: Interventional

Sponsor: Baxter Healthcare Corporation

Contact Information:
Jessica Hart
615-807-4023
jessica.hart@psysolutions.com

Back to Top

Location: Knoxville
Thompson Cancer Survival Center

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Crystal M. Dugger
865-541-2421

Back to Top

Location: Memphis
Baptist Memorial Hospital- Memphis

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Pat Gish
901-226-0033

Back to Top

Location: Memphis
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild to Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Not yet recruiting

Study Dates: Start: January 2007

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Kenneth Sakauye
877-379-3718

Back to Top

Location: Nashville
Meharry Medical College

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
N/A

Back to Top

Location: Nashville
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild to Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Not yet recruiting

Study Dates: Start: January 2007

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Harry Gwirtsman
877-379-3718

Back to Top

Location: Nashville
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy to Acetylcholinesterase Inhibitors In Mild To Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD) when combined with one of the currently approved AD medications, Aricept®, Razadyne® or Exelon®. RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Recruiting

Study Dates: Start: July 2006

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
William Petrie
877-379-3718

Back to Top

Location: Oak Ridge
Methodist Regional Cancer Center

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Brenda S. Morris
865-481-1664
bmorris@covhlth.com

Back to Top

TEXAS

Location: Austin
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy to Acetylcholinesterase Inhibitors In Mild To Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD) when combined with one of the currently approved AD medications, Aricept®, Razadyne® or Exelon®. RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Recruiting

Study Dates: Start: July 2006

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Jaron Winston
877-379-3718

Back to Top

Location: Dallas
University of Texas, Southwestern Medical Center

Trial Title and Description: A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease

The purpose of this study is to determine whether IGIV, 10% treatment, administered at two different doses for 9 and 18 months, results in a significantly slower rate of decline of dementia symptoms in subjects with mild to moderate Alzheimer’s Disease (AD). Subjects will be randomly assigned to receive intravenous infusions of either of two doses of IGIV, 10% or placebo every two weeks for 70 weeks (36 infusions) as an add-on to conventional Food and Drug Administration (FDA)-approved AD medications.

Enrollment Status: Recruiting
Study Dates: Start: December 2008
Condition: Alzheimer’s disease
Age Eligibility: 50-89
Gender Eligibility: Both
Enrollment Goal: 360
Clinical Identifier: NCT00818662
Study Phase: Phase 3
Study Type: Interventional

Sponsor: Baxter Healthcare Corporation

Contact Information:
Charlotte Isah
214-648-9310
charlotte.isah@utsouthwestern.edu
For more information, visit www.gapstudy.com

Back to Top

Location: Dallas
Methodist Hospitals of Dallas

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Mary Padilla
214-947-3621
marypadilla@mhd.com

Back to Top

Location: DeSoto
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild to Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Not yet recruiting

Study Dates: Start: January 2007

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Raj Shiwach
877-379-3718

Back to Top

Location: Houston
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy to Acetylcholinesterase Inhibitors In Mild To Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD) when combined with one of the currently approved AD medications, Aricept®, Razadyne® or Exelon®. RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Recruiting

Study Dates: Start: July 2006

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Rachelle Doody
877-379-3718

Back to Top

Location: San Antonio
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild to Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Not yet recruiting

Study Dates: Start: January 2007

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Thomas Weiss
877-379-3718

Donald Royall

Back to Top

Location: Temple
Scott & White CCOP

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Laresa A. Trusty
254-724-8384
ltrusty@swmail.sw.org

Back to Top

UTAH

Location: Salt Lake City
University of Utah Center for Alzheimer’s Care, Imaging and Research

Trial Title and Description: A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease

The purpose of this study is to determine whether IGIV, 10% treatment, administered at two different doses for 9 and 18 months, results in a significantly slower rate of decline of dementia symptoms in subjects with mild to moderate Alzheimer’s Disease (AD). Subjects will be randomly assigned to receive intravenous infusions of either of two doses of IGIV, 10% or placebo every two weeks for 70 weeks (36 infusions) as an add-on to conventional Food and Drug Administration (FDA)-approved AD medications.

Enrollment Status: Recruiting
Study Dates: Start: December 2008
Condition: Alzheimer’s disease
Age Eligibility: 50-89
Gender Eligibility: Both
Enrollment Goal: 360
Clinical Identifier: NCT00818662
Study Phase: Phase 3
Study Type: Interventional

Sponsor: Baxter Healthcare Corporation

Contact Information:
Courtney Montgomery
801-587-8385
courtney.montgomery@hsc.utah.edu

Back to Top

Location: South OgdenGSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy to Acetylcholinesterase Inhibitors In Mild To Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD) when combined with one of the currently approved AD medications, Aricept®, Razadyne® or Exelon®. RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Recruiting

Study Dates: Start: July 2006

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Navin Varma
877-379-3718

Back to Top

VERMONT

Location: Bennington
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy to Acetylcholinesterase Inhibitors In Mild To Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD) when combined with one of the currently approved AD medications, Aricept®, Razadyne® or Exelon®. RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Recruiting

Study Dates: Start: July 2006

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Lisa Catapano-Friedman
877-379-3718

Back to Top

VIRGINIA

Location: Williamsburg
Riverside Center for Excellence in Aging and Lifelong Health

Trial Title and Description: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 26-Week, Phase 3 Study of Two Doses of EVP-6124 or Placebo in Subjects with Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication

Enrollment Status: Recruiting

Study Dates: October 2013 to January 2017

Condition: Mild to Moderate Alzheimer's disease
Age Eligibility: 55-85
Gender Eligibility: Male or Female
Enrollment Goal: 790
Clinical Identifier: NCT01969136
Study Phase: Phase 3
Study Type: Interventional

Sponsor: Forum Pharmaceuticals

Contact Information:
Keri Allen
757-969-6904
Kerianne.Allen@rivhs.com

Back to Top

Location: Alexandria
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild to Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Not yet recruiting

Study Dates: Start: January 2007

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Stuart Stark
877-379-3718

Back to Top

Location:Williamsburg
Riverside Center for Excellence in Aging and Lifelong Health

Trial Title and Description: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 26-Week, Phase 3 Study of Two Doses of EVP-6124 or Placebo in Subjects with Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication

Enrollment Status: Recruiting

Study Dates: October 2013 to January 2017

Condition: Mild to Moderate Alzheimer's disease
Age Eligibility: 55-85
Gender Eligibility: Both
Enrollment Goal: 790
Clinical Identifier: NCT01969136
Study Phase: Phase 3
Study Type: Interventional

Sponsor: Forum Pharmaceuticals

Contact Information:
Keri Allen
757-969-6904
Kerianne.Allen@rivhs.com

Back to Top

WASHINGTON

Location: Bellingham
Cascadia Clinical Trials at St. Joseph Hospital

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Lorina Hall
360-738-6756

Back to Top

Location: Seattle
University of Washington

Trial Title and Description: Anti-Oxidant Treatment of Alzheimer's Disease-

The purpose of this study is to examine the safety and effectiveness of two anti-oxidant treatment regimens in patients with mild to moderate Alzheimer's disease. The anti-oxidant treatments include vitamin E + C + alpha-lipoic acid, and Coenzyme Q (CoQ).

Enrollment Status: Recruiting

Study Dates: Start: January 2006

Condition: Alzheimer's disease
Age Eligibility: 60-85
Gender Eligibility: Both
Enrollment Goal: 75
Clinical Identifier: NCT00117403
Study Phase: Phase 1
Study Type: Interventional

Sponsor: National Institute on Aging (NIA)

Contact Information:
Elaine Peskind
800-317-5382

Back to Top

Location: Seattle
Northwest Hospital

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Jennifer Armstrong
206-368-6599

Back to Top

Location: Seattle
Swedish Medical Center

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Jackie Dahlgren
206-215-3245

Back to Top

Location: Seattle
Virginia Mason CCOP

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Beth Edelheit
206-341-0446
beth.edelheit@vmmc.org

Back to Top

Location: Call for details

Trial Title and Description: Using Behavioral Programs to Treat Sleep Problems in Individuals With Alzheimer's Disease-

This study will compare four different behavioral treatment programs to determine which is most effective in reducing night-time disturbances in individuals with Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: September 2005

Condition: Alzheimer's disease, Sleep initiation and maintenance disorders
Age Eligibility: 55 and above
Gender Eligibility: Both
Enrollment Goal: 136
Clinical Identifier: NCT00183378
Study Phase: N/A
Study Type: Interventional

Sponsor: National Institute of Mental Health

Contact Information:
Amy Moore
206-616-5550
amoore@u.washington.edu

Back to Top

WISCONSIN

Location: Madison
University of Wisconsin

Trial Title and Description: A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease

The purpose of this study is to determine whether IGIV, 10% treatment, administered at two different doses for 9 and 18 months, results in a significantly slower rate of decline of dementia symptoms in subjects with mild to moderate Alzheimer’s Disease (AD). Subjects will be randomly assigned to receive intravenous infusions of either of two doses of IGIV, 10% or placebo every two weeks for 70 weeks (36 infusions) as an add-on to conventional Food and Drug Administration (FDA)-approved AD medications.

Enrollment Status: Recruiting
Study Dates: Start: December 2008
Condition: Alzheimer’s disease
Age Eligibility: 50-89
Gender Eligibility: Both
Enrollment Goal: 360
Clinical Identifier: NCT00818662
Study Phase: Phase 3
Study Type: Interventional

Sponsor: Baxter Healthcare Corporation

Contact Information:
Maia Wroblewski
608-256-1901, ext 11514
mkwrob@medicine.wisc.edu

Back to Top

Location: Marshfield
Marshfield Clinic

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Debbie Schillinger
715-387-9521
schillid@mmrfmfldclin.edu

Back to Top

Location: Milwaukee
Sinai Samaritan Medical Center

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Nancy Briggs
414-219-7370
nancy_brriggs@aurorra.org

Back to Top


For more information, connect with the Alzheimer’s Foundation of America’s licensed social workers. Click here or call 866.232.8484. Real People. Real Care.